242 related articles for article (PubMed ID: 32734668)
41. Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.
Ogawa M; Yokoyama K; Hirano M; Jimbo K; Ochi K; Kawamata T; Ohno N; Shimizu E; Yokoyama N; Yamaguchi R; Imoto S; Uchimaru K; Takahashi N; Miyano S; Imai Y; Tojo A
Br J Haematol; 2018 Dec; 183(5):842-845. PubMed ID: 29265350
[No Abstract] [Full Text] [Related]
42. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
[TBL] [Abstract][Full Text] [Related]
43. Philadelphia-positive acute lymphoblastic leukemia: current treatment options.
Liu-Dumlao T; Kantarjian H; Thomas DA; O'Brien S; Ravandi F
Curr Oncol Rep; 2012 Oct; 14(5):387-94. PubMed ID: 22669492
[TBL] [Abstract][Full Text] [Related]
44. Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
Canet J; Cony-Makhoul P; Orazio S; Cornet E; Troussard X; Maynadié M; Étienne G; Monnereau A
Cancer Med; 2021 Oct; 10(20):6959-6970. PubMed ID: 34551198
[TBL] [Abstract][Full Text] [Related]
45. As leukemia options grow, drugs jockey to be first-line therapies.
Dolgin E
Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994
[No Abstract] [Full Text] [Related]
46. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
48. Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients.
Kaeda J; Ringel F; Oberender C; Gresse M; Amini L; Schwarz M; Dörken B; le Coutre P
Acta Haematol; 2016; 136(1):62-4. PubMed ID: 27160312
[No Abstract] [Full Text] [Related]
49. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
50. New strategies in controlling drug resistance.
Frame D
J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):13-7. PubMed ID: 17970610
[TBL] [Abstract][Full Text] [Related]
51. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD
Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747
[TBL] [Abstract][Full Text] [Related]
52. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
53. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
[TBL] [Abstract][Full Text] [Related]
54. Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.
Brümmendorf TH; Cortes JE; Khoury HJ; Kantarjian HM; Kim DW; Schafhausen P; Conlan MG; Shapiro M; Turnbull K; Leip E; Gambacorti-Passerini C; Lipton JH
Br J Haematol; 2016 Jan; 172(1):97-110. PubMed ID: 26537529
[TBL] [Abstract][Full Text] [Related]
55. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Hall KH; Brooks A; Waller EK
Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
[No Abstract] [Full Text] [Related]
56. Paediatric chronic myeloid leukaemia: Is it really a different disease?
Pushpam D; Bakhshi S
Indian J Med Res; 2019 May; 149(5):600-609. PubMed ID: 31417027
[TBL] [Abstract][Full Text] [Related]
57. Tyrosine kinase inhibitors: the first decade.
Agrawal M; Garg RJ; Cortes J; Quintás-Cardama A
Curr Hematol Malig Rep; 2010 Apr; 5(2):70-80. PubMed ID: 20425399
[TBL] [Abstract][Full Text] [Related]
58. Characterization of cancer stem cells in chronic myeloid leukaemia.
Jørgensen HG; Holyoake TL
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
[TBL] [Abstract][Full Text] [Related]
59. [Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Hochhaus A; Berger U; Reiter A; Engelich G; Lahaye T; Kreil S; Merx K; Müller MC; Hehlmann R
Internist (Berl); 2002 Oct; 43(10):1228, 1231-8, 1241-4. PubMed ID: 12524904
[No Abstract] [Full Text] [Related]
60. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Hochhaus A; Kantarjian HM; Baccarani M; Lipton JH; Apperley JF; Druker BJ; Facon T; Goldberg SL; Cervantes F; Niederwieser D; Silver RT; Stone RM; Hughes TP; Muller MC; Ezzeddine R; Countouriotis AM; Shah NP
Blood; 2007 Mar; 109(6):2303-9. PubMed ID: 17138817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]